The 10 most recent market catalysts affecting $PLSE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 65
BTIG Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $70
BTIG's initiation of coverage on Pulse Biosciences with a 'Buy' rating and a $70 price target is a positive development for the company. Analyst coverage often brings increased vis…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 65
Pulse Biosciences Concludes 100 Patient Enrollment in PRECISE-BTN Study of nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences announced the completion of enrollment for its PRECISE-BTN clinical study, which evaluates its nPulse Vybrance Percutaneous Electrode System for symptomatic benig…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 75
Pulse Biosciences shares are trading higher after Freedom Capital Markets initiated coverage on the stock with a Buy rating and announced a $73 price target.
The initiation of coverage with a 'Buy' rating and a substantial price target from a financial institution like Freedom Capital Markets is a strong positive catalyst for Pulse Bios…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 65
Freedom Capital Markets Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $73
Freedom Capital Markets analyst Keith Hinton has initiated coverage on Pulse Biosciences (PLSE) with a 'Buy' rating and a $73 price target. This event is significant because new an…
Aug 17, 2026
Corporate Catalyst
Neutral
Impact 65
Needham Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $58
Needham's initiation of coverage on Pulse Biosciences with a 'Buy' rating and a $58 price target is a positive development for the company. Analyst coverage can increase visibility…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 65
Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $43
Canaccord Genuity analyst William Plovanic maintained a 'Buy' rating on Pulse Biosciences and raised the price target from $32 to $43. This analyst upgrade suggests increased confi…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 75
Pulse Biosciences shares are trading higher after the company reported Q2 financial results. The stock initially fell yesterday after the market closed, but it has since reversed.
This headline indicates a strong corporate catalyst for Pulse Biosciences. The initial dip after hours, followed by a significant reversal, suggests that investors may have initial…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 85
Pulse Biosciences shares are trading lower after the company reported worse-than-expected Q2 sales results.
This headline represents a significant corporate catalyst directly impacting Pulse Biosciences. Worse-than-expected sales results often lead to immediate negative investor sentimen…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 85
Pulse Biosciences Q2 EPS $(0.36), Inline, Sales $434.000K Miss $533.333K Estimate
Pulse Biosciences announced Q2 earnings where EPS of $(0.36) met analyst consensus, but sales of $434,000 missed estimates by 18.62%. This is a significant revenue miss, suggesting…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 75
Pulse Biosciences Says NANOPULSE-AF Atrial Fibrillation Study Surpasses Enrollment Midpoint After April 2026 Start; Update Due On August 6 Earnings Call
This headline is a significant corporate catalyst for Pulse Biosciences (PLSE). Surpassing the enrollment midpoint for a pivotal clinical trial, especially ahead of a relatively re…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.